Bemarituzumab (Anti-FGFR2 / CD332)
Bemarituzumab (Anti-FGFR2 / CD332) (A2497-GRP)
Products
Description
Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2497 |
| Target | FGFR |